ClinicalTrials.gg
Active, not recruitingNCT04526665ELATIVEUpdated Nov 5, 2026Results posted

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

A Phase 3 interventional study of Elafibranor 80mg and Placebo in Primary Biliary Cirrhosis, sponsored by Ipsen. Active, not recruiting at 115 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Liver Cirrhosis, Biliary by Ipsen — 3 open to participants now, 6 under way, 3 of them phase 3. Liver Cirrhosis, Biliary · Ipsen.

Started
2020
the only one that year
Phase 3
4 of 10
1 open now
Registered
3rd of 10
by date

Among the 10 studies in Liver Cirrhosis, Biliary by Ipsen, this one is the only one that started in 2020, is one of 4 in phase 3, and was the 3rd registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

3 of the 10 studies in Liver Cirrhosis, Biliary by Ipsen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Cirrhosis, Biliary by Ipsen, or all of them as a file.
02

Study summary

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease).

PBC is a slowly progressive disease characterized by damage of the bile ducts in the liver, leading to a buildup of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done.

The main aim of this study is to determine if elafibranor (the study drug) is better than placebo (a dummy treatment) at decreasing the levels of a specific blood test (alkaline phosphatase) that provides information about participant's disease. This study will also evaluate the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itchy skin (pruritus) and tiredness (fatigue).

This study has two main parts:

Part 1 will compare a daily dose of elafibranor to a daily dose of placebo and will last between a minimum of one year and a maximum of two years.

Part 2, all participants will receive elafibranor for a period of up to 5 years or until the total treatment duration (part 1 and part 2) reaches 6 years, whichever occurs first.

03

Conditions studied

  • Primary Biliary Cirrhosis

Keywords

  • Primary Biliary Cholangitis
  • PBC
  • Elafibranor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females age of 18 to 75 years (inclusive)
  • Definite or probable Primary biliary cholangitis (PBC) diagnosis
  • Alkaline phosphatase (ALP) ≥ 1.67x (ULN)
  • Total (TB) ≤ 2x ULN
  • Ursodeoxycholic acid (UDCA) for at least 12 months (stable dose ≥ 3 months) prior to screening, or unable to tolerate UDCA treatment (no UDCA for ≥ 3 months) prior to screening (per country standard-of-care dosing)
  • Must have PBC Worst Itch Numeric rating scale (NRS) collected prior to randomization
  • Females participating in this study must be of non-child bearing potential or must be using highly efficient for the full duration of the study and for 1 month after the last drug intake

Exclusion criteria

Exclusion Criteria:

  • History or presence of other concomitant liver disease
  • hepatic decompensation, including patients with complications of cirrhosis/portal hypertension
  • Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease) or which may diminish to \< 2 years, including known cancers
  • Patient has a positive test for Type 1 or 2 at screening, or patient is known to have tested positive for HIV
  • Evidence of any other unstable or untreated clinically significant disease
  • History of alcohol abuse
  • For female patients: known pregnancy or lactating
  • Use of fibrates and glitazones within 2 months prior to screening
  • Use of Obeticholic acid (OCA), azathioprine, cyclosporine, methotrexate, mycophenolate, pentoxifylline, budesonide and other systemic (parenteral and oral chronic administration only); potentially hepatotoxic drugs
  • (including α-methyl-dopa, sodium valproic acid isoniazid, or nitrofurantoin) within 3 months prior to screening
  • Use of antibodies or immunotherapy directed against interleukins (ILs) or other cytokines or chemokines within 12 months prior to screening
  • For patients with previous exposure to OCA, OCA should be discontinued 3 months prior to screening
  • Patients who are currently participating in, plan to participate in, or have participated in an drug study or medical device study containing active substance within 30 days or five half-lives, whichever is longer, prior to screening; for patients with previous exposure to seladelpar, seladelpar should be discontinued 3 months prior to screening
  • (ALT) and/or Aspartate aminotransferase (AST) values > 5 x
  • For patients with AT or TB>ULN at SV1, variability of AT or TB > 40% (see section 3.5.1)
  • Albumin\<3.0 g/dl
  • Severely advanced patients according to Rotterdam criteria (TB > ULN and albumin \<LLN)
  • > 1.3 due to altered hepatic function
  • CPK > 2 x ULN
  • Screening serum creatinine > 1.5 mg/dl
  • Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as patients with markers of kidney failure damage or \< 60 mL/min/1.73 m\^2) calculated by Modification of diet in renal disease (MDRD)
  • count \< 150 x 10\^3/μL
  • AFP > 20 ng/mL with 4-phase liver CT or MRI imaging suggesting presence of liver cancer
  • Known to the investigational product or to any of the formulation of the elafibranor or placebo tablet Mental instability or incompetence, such that the validity of or ability to be compliant with the study is uncertain
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Elafibranor 80mg double-blind

    Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning

    Drug: Elafibranor 80mg

  • Placebo comparator
    Placebo

    Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning

    Drug: Placebo

  • Experimental
    Elafibranor 80mg open label

    Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning

    Drug: Elafibranor 80mg

Interventions

  • Elafibranor 80mg daily

    Also known as: Iqirvo®

  • DrugPlacebo

    Placebo daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52

    Cholestasis response was defined as alkaline phosphatase (ALP) \< 1.67 x upper limit of normal (ULN) and total bilirubin (TB) \<= ULN and ALP decrease from baseline \>= 15% at Week 52 and based on the composite strategy imputing non-response for participants who experienced intercurrent events (ICEs) (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

    Time frame: At Week 52

Secondary outcomes

  1. Key Secondary Endpoint: Percentage of Participants With Response to Treatment Based on ALP Normalization at Week 52

    Response to treatment based on normalization of ALP at Week 52 was defined as percentage of participants with ALP =\<1.0× ULN and based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

    Time frame: At Week 52

  2. Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch Numeric Rating Scale (NRS) Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 52

    The PBC Worst Itch NRS is a simple, self-administered patient reported outcome (PRO) questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).

    Time frame: Baseline (up to 14 days pre-dose) and Week 52

  3. Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch NRS Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 24

    The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).

    Time frame: Baseline (up to 14 days pre-dose) and Week 24

  4. Change From Baseline in ALP at Weeks 4, 13, 26, 39 and 52

    Blood samples were collected at specified timepoints for assessment of ALP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Weeks 4, 13, 26, 39 and 52

  5. Percentage of Participants With ALP Response From Baseline at Week 52

    ALP response was defined as ALP decrease from baseline \>= 10%; ALP decrease from baseline \>= 20% and ALP decrease from baseline \>= 40% at Week 52 and based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  6. Percentage of Participants With Response to Treatment According to ALP < 1.5x ULN, ALP Decrease From Baseline >= 40% and TB =<ULN at Week 52

    Response to treatment was according to ALP \< 1.5x ULN, ALP decrease from baseline \>= 40% and TB =\<ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: At Week 52

  7. Percentage of Participants With Response to Treatment According to ALP < 3x ULN, Aspartate Aminotransferase (AST) < 2x ULN and TB =< 1 Milligrams Per Deciliter (mg/dL) (Paris I) at Week 52

    Response to treatment was according to ALP \< 3x ULN, AST \< 2x ULN and TB =\< 1 mg/dL (Paris I) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

    Time frame: At Week 52

  8. Percentage of Participants With Response to Treatment According to ALP =< 1.5x ULN, AST =< 1.5x ULN and TB =< 1 mg/dL (Paris II) at Week 52

    Response to treatment was according to ALP =\< 1.5x ULN, AST =\< 1.5x ULN and TB =\< 1 mg/dL (Paris II) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

    Time frame: At Week 52

  9. Percentage of Participants With Response to Treatment According to TB Decrease of 15% Change From Baseline at Week 52

    Response to treatment was according to TB decrease of 15% change from baseline at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: At Week 52

  10. Percentage of Participants With Response to Treatment According to Normalization of TB (TB =< ULN) and/or Albumin (ALB >= Lower Limit of Normal [LLN]) (Rotterdam) at Week 52

    Response to treatment was according to TB (TB =\< ULN) and/or albumin (ALB \>= LLN) (Rotterdam) at week 52. Participant was considered as responder at Week 52 only if total bilirubin and albumin were normal. The endpoint was analyzed in participants with abnormal total bilirubin (TB \> ULN) or albumin (ALB \< LLN) at baseline. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

    Time frame: At Week 52

  11. Percentage of Participants With Response to Treatment According to TB ≤0.6 x ULN at Week 52

    Response to treatment was according to TB ≤0.6 x ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

    Time frame: At Week 52

  12. Percentage of Participants With Response to Treatment According to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 52

    Response to treatment was according to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

    Time frame: At Week 52

  13. Percentage of Participants With Response to Treatment According to no Worsening of TB at Week 52

    Response to treatment was according to no worsening of TB, which was defined as level of TB \<ULN or no increase from baseline of more than 0.1 x ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

    Time frame: At Week 52

  14. Percentage of Participants With Response to Treatment According to Complete Biochemical Response at Week 52

    Response to treatment according to complete biochemical response which was defined as \<= ULN values of ALP, TB, AST, ALT and ALB, and international normalized ratio (INR) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

    Time frame: At Week 52

  15. PBC 5-, 10- and 15-year Risk Scores Based on United Kingdom (UK)-PBC Score at Week 52

    The UK-PBC risk score was defined by the mean percentage risk that a PBC participant treated with UDCA would develop liver failure requiring liver transplantation in 5, 10, and 15 years from diagnosis. It is calculated from the following equation at week 52 as follows: UK-PBC score = 0.0287854\*(alpEPxULN-1.722136304) - 0.0422873\*(\[{altastEP x ULN/10}\^-1\] - 8.675729006) + 1.4199 \* (LN(bilEPxULN /10)+2.709607778) - 1.960303\*(alb x LLN -1.17673001)-0.4161954\*(plt x LLN -1.873564875). The survival S(t) for any given participants was then calculated by S(t) = S0(t) exp(UK-PBC score). Here, alpEP x ULN=ALP /Upper Level Normal ALP at the timepoint, altastEPxULN=(ALT, AST or TA) /upper level normal of the value at the timepoint, bilEP x ULN=bilirubin /upper level normal bilirubin at the timepoint, alb x LLN=alb /alb lower level normal at baseline and plt x LLN=plt/plt lower level normal at baseline. Lower UK-PBC score predicts lower risk and better prognosis.

    Time frame: At Week 52

  16. Global PBC Study Group (GLOBE) Score at Week 52

    The GLOBE score was a validated risk assessment tool providing an estimate of transplant-free survival for participants with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 participants with PBC. It is calculated from the following equation at week 52 as follows: GLOBE score = 0.044378 \* age at start of ursodeoxycholic acid (UDCA) therapy + 0.93982 \* LN (TB x ULN) + 0.335648 \* LN (ALP x ULN) - 2.266708 \* ALB x LLN - 0.002581 \* platelet count per 10\^9/L) + 1.216865; where TB x ULN = bilirubin/ULN at the timepoint, ALP x ULN = ALP/ULN at the timepoint, ALB x LLN = ALB/LLN at the timepoint, platelet count per 10\^9/L = platelet count per 10\^9/L at the timepoint. The Lower GLOBE PBC score predicts lower risk and better prognosis.

    Time frame: At Week 52

  17. Change From Baseline in Hepatobiliary Injury and Liver Function as Assessed by AST, ALT, Gamma-glutamyl Transferase (GGT), 5 Prime Nucleotidase (5'-NT), and Fractionated ALP (Hepatic) (H1 and H2) at Week 52

    Hepatobiliary injury and liver function were assessed as measured by AST, ALT, GGT, 5'-NT, and fractionated ALP (hepatic) (H1 and H2). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  18. Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by Total and Conjugated Bilirubin at Week 52

    Hepatobiliary injury and liver function were assessed as measured by total and conjugated bilirubin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  19. Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by Albumin at Week 52

    Hepatobiliary injury and liver function were assessed as measured by albumin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  20. Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by INR at Week 52

    Hepatobiliary injury and liver function were assessed as measured by INR. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  21. Change From Baseline in Biomarkers of Inflammation as Measured by High-sensitivity C-reactive Protein (hsCRP) at Week 52

    Biomarkers of inflammation were assessed as measured by hsCRP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  22. Change From Baseline in Biomarkers of Inflammation as Measured by Fibrinogen and Haptoglobin at Week 52

    Biomarkers of inflammation were assessed as measured by fibrinogen and haptoglobin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  23. Change From Baseline in Biomarkers of Inflammation as Measured by Tumor Necrosis Factor Alpha at Week 52

    Biomarkers of inflammation were assessed as measured by TNF-alpha. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  24. Change From Baseline in Immune Response as Measured by Immunoglobulin (Ig)G and IgM at Week 52

    Immune response was assessed as measured by IgG and IgM. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  25. Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Enhanced Liver Fibrosis (ELF) and Plasminogen Activator Inhibitor-1 (PAI-1) at Week 52

    Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by ELF: hyaluronic acid \[HA\], type 2 procollagen peptide \[PIINP\], tissue inhibitor of metalloproteinases-1\[TIMP-1\]) and PAI-1. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  26. Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Cytokeratin-18 (CK-18) at Week 52

    Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by CK-18 (M30 and M65). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  27. Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Transforming Growth Factor Beta (TGF-beta) at Week 52

    Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by TGF-beta. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  28. Change From Baseline in Liver Stiffness Measured by Transient Elastography (TE) at Week 52

    FibroScan® TE device (Echosens, Paris, France) is a non-invasive technique used to measure liver stiffness, which correlated with fibrosis. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  29. Change From Baseline in Lipid Parameters at Week 52

    Blood samples were collected at specified timepoints for assessment of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol and triglycerides (TG). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  30. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52

    Blood samples were collected at specified timepoints for assessment of FPG. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  31. Change From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis at Week 52

    Blood samples were collected at specified timepoints for assessment bile acids and biomarkers of bile acid synthesis. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  32. Change From Baseline at Week 52 in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured by 7 Alpha-hydroxy-4-cholesten-3-one (C4) at Week 52

    Blood samples were collected at specified timepoints for assessment of bile acids and biomarkers of bile acid synthesis as measured by C4. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  33. Change From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured Fibroblast Growth Factor 19 at Week 52

    Blood samples were collected at specified timepoints for assessment bile acids and biomarkers of bile acid synthesis as measured by Fibroblast Growth Factor 19. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  34. Percentage of Participants With Response in PBC Worst Itch NRS Score at Weeks 24 and 52

    The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Response to PBC Worst Itch NRS was according to clinically meaningful change at least 30% reduction; one point, two points or three points decrease in score from baseline in participants with a baseline NRS score ≥4. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).

    Time frame: Baseline (up to 14 days pre-dose) and at Week 24 and Week 52

  35. Percentage of Participants With no Worsening of Pruritus as Measured by the PBC Worst Itch NRS Score at Weeks 24 and 52

    The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake). A worsening of Pruritus was defined by a positive change from baseline in PBC Worst Itch NRS score greater than 2 at week 24 and 52.

    Time frame: Baseline (up to 14 days pre-dose) and at Week 24 and Week 54

  36. Change From Baseline in 5-D Itch at Week 52

    The 5-D Itch scale is a questionnaire that has been validated in several different diseases. It assesses symptoms in terms of 5 domains: duration: score range 1 (less than 6 hours) to 5 (all day); degree: score range 1 (not present) to 5 (unbearable); duration: score range 1 (less than 6 hours) and 5 (all day); direction: score range 1(completely resolved) and 5 (getting worse); disability: score range 1 (never affects or not applicable) and 5 (delays falling asleep and frequently wakes up at night or always affects this activity) and distribution: where the question was to mark where itching is present in body parts over the last two weeks. Participants rated their symptoms over preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. The 5-D Itch total score ranged between 5 (no pruritus) and 25 (most severe pruritus). Higher scores indicated worse outcomes. Baseline= last non-missing value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  37. Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a at Week 52

    The PROMIS Fatigue Short Form 7a consists of seven items that measure both the experience of fatigue and the interference of fatigue on daily activities over the past week. Participants completed the PROMIS Fatigue Short Form 7a and answered following questions on a scale from 1 (never) to 5 (always) : "How often did you feel tired"; "How often did you experience extreme exhaustion"; "How often did you run out of energy"; "How often did your fatigue limit you at work"; "How often were you too tired to think clearly"; "How often were you too tired to take a bath or shower" and 'How often did you have enough energy to exercise strenuously". T-score values include mean of 50 and standard deviation of 10. The PROMIS Fatigue T-score ranged from 29.4 (best) to 83.2 (worst). Higher scores indicated worse outcomes. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  38. Change From Baseline in Epworth Sleepiness Scale (ESS) at Week 52

    The ESS is a short, self-administered questionnaire that consists of 8 questions asking to rate how likely it is to fall asleep in everyday situations (each question can be scored from 0 to 3 points; '0' indicates no chance of dozing and '3' indicates high chance of dozing). It provides a total score which has been shown to relate to the participant's level of daytime sleepiness (total score range 0 \[no sleepiness\] to 24 points \[significant sleepiness\]). The total score is the sum of all item scores and ranged from 0 (best) to 24 (worst). Higher scores indicated more chances of sleepiness. Participants were asked to complete the ESS with regard to the level of sleepiness they experienced over approximately the past 7 days. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  39. Change From Baseline in PBC-40 at Week 52

    PBC-40 assess symptoms across 6 domains:symptoms,itch,fatigue,cognitive,emotional and social. Participants responded on verbal response scale,depending on section options range from 'never'/'not at all'/'strongly disagree' to 'always'/'very much'/'strongly agree'.5 items (3/3 in itch domain and 2/10 in social domain)also included a 'does not apply' option.Domains:Symptoms(7 questions)score range 7-35,Itch(3 questions)score range 3-15,Fatigue(11 questions)score range 11-55,Cognitive(6 questions)score range 6-30,Emotional(3 questions)score range 3-15,Social(10 questions)score range 10-50.Score for each domain was provided(total score was not calculated),with each verbal response scale correlating to score of 1-5 per item(0-5 on items with a 'does not apply' option);5=most affected.Individual item scores are summed to give total domain score.Higher scores=worse outcomes.PBC-40 had 4-week recall period.Baseline=last non-missing value on or before first dose of randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  40. Change From Baseline in Health Utility as Measured by the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) at Week 52

    The EQ-5D-5L is a 6-item, standardized questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health state. The visual analog scale (VAS) of EQ-5D-5L questionnaire is numbered from 0 (worst) to 100 (best). Higher scores indicated better outcomes. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  41. Change From Baseline in T-Scores for Bone Mineral Density Assessed by Dual-energy X-ray Absorptiometry (DEXA) Scanning at Week 52

    DEXA scanning (hip and lumbar) was performed in participants to assess bone mineral density (femoral neck, lumbar and total hip). T-scores were calculated based on actual measured bone density value. The T-score compared a participant's bone density against that of a healthy 30-year-old adult. T-scores were used to determine primary osteoporosis, which exists on its own without any other cause and were divided into 3 categories: low risk, medium risk, and high risk (osteoporosis). T-scores measure the number of minerals in a participant's bone. A participant's level of bone loss was compared to that of a typical, healthy 30-year-old adult. A score ≥-1.0 indicates low risk, medium risk is a score between-2.5 and -1.0, and a high risk/osteoporosis is a score ≤-2.5. A positive change in T-score indicates an improvement in bone mineral density. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  42. Change From Baseline in Serum Markers of Bone Turnover Carboxy Terminal Crosslinked Telopeptides of Type 1 Collagen [CTX] at Week 52

    Blood samples were collected at specified timepoints for assessment of serum markers of bone turnover, CTX. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  43. Change From Baseline in Serum Markers of Bone Turnover Type 1 Procollagen Peptide [P1NP]) at Week 52

    Blood samples were collected at specified timepoints for assessment of serum markers of bone turnover, P1NP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

    Time frame: Baseline (Day 1) and at Week 52

  44. Percentage of Participants With Onset of Clinical Outcomes

    Onset of clinical outcomes were described as a composite endpoint composed of the following: model for end stage liver disease sodium (MELD-Na) \>14 for participants with baseline MELD-Na \<12; liver transplant; uncontrolled ascites requiring treatment; hospitalization for new onset or recurrence of any including, variceal bleed, hepatic encephalopathy defined as West-Haven score of 2 or more and spontaneous bacterial peritonitis; and death.

    Time frame: From Day 1 up to Week 52

  45. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)

    An AE was any untoward medical occurrence in a participant or clinical investigation participant who was administered an investigational product, and which does not necessarily have a causal relationship with treatment. A TEAE was defined as any AE with onset during TEAE assessment period, or any event started prior to first dose of treatment and worsened or became serious during the TEAE assessment period. An SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect. An AESI was an AE that might not be serious but was of special importance to a particular treatment or class.

    Time frame: TEAEs were collected from the start of study treatment administration (Day 1) up to DCO date of 01 June 2023, approximately 980 days.

  46. Plasma Concentrations of Elafibranor and GFT1007

    Blood samples were collected at specified timepoints to evaluate plasma concentration of Elafibranor and its metabolite GFT1007.

    Time frame: Week 4: pre-dose, 0.5 hour, 1.5 hours, between 2-3 hours, 4 hours and 6 hours post-dose

07

Results

Posted Sep 5, 2024

Participant flow

This Phase III, double-blind (DB), placebo-controlled study followed by an open-label long-term extension (LTE) was conducted in participants with primary biliary cholangitis (PBC) at 82 sites in 14 countries (Argentina, Belgium, Brazil, Canada, Chile, France, Germany, Italy, South Africa, Spain, Switzerland, Turkey, United Kingdom, and United States). First participant was recruited on 24 September 2020 and data cut-off (DCO) date was 01 June 2023.

Participant flow — Overall Study
MilestoneElafibranor 80 mgPlacebo
Started10853
Completed9446
Not completed147
Withdrew: Withdrawal by subject63
Withdrew: Adverse event41
Withdrew: Physician decision22
Withdrew: Death20
Withdrew: Other01

Outcome measures

PrimaryPercentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52

Cholestasis response was defined as alkaline phosphatase (ALP) \< 1.67 x upper limit of normal (ULN) and total bilirubin (TB) \<= ULN and ALP decrease from baseline \>= 15% at Week 52 and based on the composite strategy imputing non-response for participants who experienced intercurrent events (ICEs) (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 5250.9 (41.6 to 60.2)3.8 (1.0 to 12.8)
Statistical analysis
  • Elafibranor 80 mg vs Placebo · Exact Cochran-Mantel-Haenszel test · p = <0.0001 · Odds ratio (or): 37.562 · 95% CI 7.641 to 302.247Exact Cochran-Mantel-Haenszel test stratified by the randomization factors (ALP \>3xULN or TB\>ULN:Yes/No, and Baseline PBC Worst Itch NRS ≥ 4: Yes/No)
SecondaryKey Secondary Endpoint: Percentage of Participants With Response to Treatment Based on ALP Normalization at Week 52

Response to treatment based on normalization of ALP at Week 52 was defined as percentage of participants with ALP =\<1.0× ULN and based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Key Secondary Endpoint: Percentage of Participants With Response to Treatment Based on ALP Normalization at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
Key Secondary Endpoint: Percentage of Participants With Response to Treatment Based on ALP Normalization at Week 5214.8 (9.3 to 22.7)0 (0.0 to 6.8)
SecondaryKey Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch Numeric Rating Scale (NRS) Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 52

The PBC Worst Itch NRS is a simple, self-administered patient reported outcome (PRO) questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).

Time frame:
Baseline (up to 14 days pre-dose) and Week 52
Reported as:
Least squares mean · Scores on a scale
Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch Numeric Rating Scale (NRS) Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 52
Scores on a scaleElafibranor 80 mgPlacebo
Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch Numeric Rating Scale (NRS) Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 52-1.930 (-2.602 to -1.258)-1.146 (-2.143 to -0.150)
Statistical analysis
  • Elafibranor 80 mg vs Placebo · mixed model for repeated measures (MMRM) · p = 0.1970 · Least square mean difference: -0.784 · 95% CI -1.986 to 0.418
SecondaryKey Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch NRS Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 24

The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).

Time frame:
Baseline (up to 14 days pre-dose) and Week 24
Reported as:
Least squares mean · Scores on a scale
Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch NRS Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 24
Scores on a scaleElafibranor 80 mgPlacebo
Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch NRS Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 24-1.598 (-2.246 to -0.951)-1.255 (-2.201 to -0.309)
Statistical analysis
  • Elafibranor 80 mg vs Placebo · MMRM · p = 0.5522 · Least square mean difference: -0.343 · 95% CI -1.489 to 0.803MMRM with treatment, 4-week period and treatment by 4-week period interaction as fixed factors and adjusting for baseline and stratification factors.
SecondaryChange From Baseline in ALP at Weeks 4, 13, 26, 39 and 52

Blood samples were collected at specified timepoints for assessment of ALP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Weeks 4, 13, 26, 39 and 52
Reported as:
Mean · Units per Liter (U/L)
Change From Baseline in ALP at Weeks 4, 13, 26, 39 and 52
Units per Liter (U/L)Elafibranor 80 mgPlacebo
Week 4-116.4 ± 63.1-14.3 ± 92.6
Week 13-131.8 ± 74.6-19.1 ± 78.3
Week 26-126.2 ± 85.5-6.0 ± 75.6
Week 39-134.7 ± 89.8-20.0 ± 90.1
Week 52-117.7 ± 96.5-8.8 ± 91.2
SecondaryPercentage of Participants With ALP Response From Baseline at Week 52

ALP response was defined as ALP decrease from baseline \>= 10%; ALP decrease from baseline \>= 20% and ALP decrease from baseline \>= 40% at Week 52 and based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With ALP Response From Baseline at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
ALP response >= 10% decrease from baseline75.522.6
ALP response >= 20% decrease from baseline69.85.7
ALP response >= 40% decrease from baseline54.70.0
SecondaryPercentage of Participants With Response to Treatment According to ALP < 1.5x ULN, ALP Decrease From Baseline >= 40% and TB =<ULN at Week 52

Response to treatment was according to ALP \< 1.5x ULN, ALP decrease from baseline \>= 40% and TB =\<ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Response to Treatment According to ALP < 1.5x ULN, ALP Decrease From Baseline >= 40% and TB =<ULN at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
Percentage of Participants With Response to Treatment According to ALP < 1.5x ULN, ALP Decrease From Baseline >= 40% and TB =<ULN at Week 5237.70.0
SecondaryPercentage of Participants With Response to Treatment According to ALP < 3x ULN, Aspartate Aminotransferase (AST) < 2x ULN and TB =< 1 Milligrams Per Deciliter (mg/dL) (Paris I) at Week 52

Response to treatment was according to ALP \< 3x ULN, AST \< 2x ULN and TB =\< 1 mg/dL (Paris I) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Response to Treatment According to ALP < 3x ULN, Aspartate Aminotransferase (AST) < 2x ULN and TB =< 1 Milligrams Per Deciliter (mg/dL) (Paris I) at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
Percentage of Participants With Response to Treatment According to ALP < 3x ULN, Aspartate Aminotransferase (AST) < 2x ULN and TB =< 1 Milligrams Per Deciliter (mg/dL) (Paris I) at Week 5268.947.2
SecondaryPercentage of Participants With Response to Treatment According to ALP =< 1.5x ULN, AST =< 1.5x ULN and TB =< 1 mg/dL (Paris II) at Week 52

Response to treatment was according to ALP =\< 1.5x ULN, AST =\< 1.5x ULN and TB =\< 1 mg/dL (Paris II) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Response to Treatment According to ALP =< 1.5x ULN, AST =< 1.5x ULN and TB =< 1 mg/dL (Paris II) at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
Percentage of Participants With Response to Treatment According to ALP =< 1.5x ULN, AST =< 1.5x ULN and TB =< 1 mg/dL (Paris II) at Week 5243.05.7
SecondaryPercentage of Participants With Response to Treatment According to TB Decrease of 15% Change From Baseline at Week 52

Response to treatment was according to TB decrease of 15% change from baseline at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Response to Treatment According to TB Decrease of 15% Change From Baseline at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
Percentage of Participants With Response to Treatment According to TB Decrease of 15% Change From Baseline at Week 5231.422.6
SecondaryPercentage of Participants With Response to Treatment According to Normalization of TB (TB =< ULN) and/or Albumin (ALB >= Lower Limit of Normal [LLN]) (Rotterdam) at Week 52

Response to treatment was according to TB (TB =\< ULN) and/or albumin (ALB \>= LLN) (Rotterdam) at week 52. Participant was considered as responder at Week 52 only if total bilirubin and albumin were normal. The endpoint was analyzed in participants with abnormal total bilirubin (TB \> ULN) or albumin (ALB \< LLN) at baseline. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Response to Treatment According to Normalization of TB (TB =< ULN) and/or Albumin (ALB >= Lower Limit of Normal [LLN]) (Rotterdam) at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
TB (TB =< ULN)25.050.0
SecondaryPercentage of Participants With Response to Treatment According to TB ≤0.6 x ULN at Week 52

Response to treatment was according to TB ≤0.6 x ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Response to Treatment According to TB ≤0.6 x ULN at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
Percentage of Participants With Response to Treatment According to TB ≤0.6 x ULN at Week 5274.377.4
SecondaryPercentage of Participants With Response to Treatment According to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 52

Response to treatment was according to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Response to Treatment According to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
Percentage of Participants With Response to Treatment According to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 5251.99.4
SecondaryPercentage of Participants With Response to Treatment According to no Worsening of TB at Week 52

Response to treatment was according to no worsening of TB, which was defined as level of TB \<ULN or no increase from baseline of more than 0.1 x ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Response to Treatment According to no Worsening of TB at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
Percentage of Participants With Response to Treatment According to no Worsening of TB at Week 5285.783.0
SecondaryPercentage of Participants With Response to Treatment According to Complete Biochemical Response at Week 52

Response to treatment according to complete biochemical response which was defined as \<= ULN values of ALP, TB, AST, ALT and ALB, and international normalized ratio (INR) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Response to Treatment According to Complete Biochemical Response at Week 52
Percentage of participantsElafibranor 80 mgPlacebo
Percentage of Participants With Response to Treatment According to Complete Biochemical Response at Week 529.30.0
SecondaryPBC 5-, 10- and 15-year Risk Scores Based on United Kingdom (UK)-PBC Score at Week 52

The UK-PBC risk score was defined by the mean percentage risk that a PBC participant treated with UDCA would develop liver failure requiring liver transplantation in 5, 10, and 15 years from diagnosis. It is calculated from the following equation at week 52 as follows: UK-PBC score = 0.0287854\*(alpEPxULN-1.722136304) - 0.0422873\*(\[{altastEP x ULN/10}\^-1\] - 8.675729006) + 1.4199 \* (LN(bilEPxULN /10)+2.709607778) - 1.960303\*(alb x LLN -1.17673001)-0.4161954\*(plt x LLN -1.873564875). The survival S(t) for any given participants was then calculated by S(t) = S0(t) exp(UK-PBC score). Here, alpEP x ULN=ALP /Upper Level Normal ALP at the timepoint, altastEPxULN=(ALT, AST or TA) /upper level normal of the value at the timepoint, bilEP x ULN=bilirubin /upper level normal bilirubin at the timepoint, alb x LLN=alb /alb lower level normal at baseline and plt x LLN=plt/plt lower level normal at baseline. Lower UK-PBC score predicts lower risk and better prognosis.

Time frame:
At Week 52
Reported as:
Mean · Scores on a scale
PBC 5-, 10- and 15-year Risk Scores Based on United Kingdom (UK)-PBC Score at Week 52
Scores on a scaleElafibranor 80 mgPlacebo
UK PBC 5-year risk score0.0102 ± 0.01260.0146 ± 0.0264
UK PBC 10-year risk score0.0330 ± 0.03930.0454 ± 0.0731
UK PBC 15-year risk score0.0593 ± 0.06700.0786 ± 0.1109
SecondaryGlobal PBC Study Group (GLOBE) Score at Week 52

The GLOBE score was a validated risk assessment tool providing an estimate of transplant-free survival for participants with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 participants with PBC. It is calculated from the following equation at week 52 as follows: GLOBE score = 0.044378 \* age at start of ursodeoxycholic acid (UDCA) therapy + 0.93982 \* LN (TB x ULN) + 0.335648 \* LN (ALP x ULN) - 2.266708 \* ALB x LLN - 0.002581 \* platelet count per 10\^9/L) + 1.216865; where TB x ULN = bilirubin/ULN at the timepoint, ALP x ULN = ALP/ULN at the timepoint, ALB x LLN = ALB/LLN at the timepoint, platelet count per 10\^9/L = platelet count per 10\^9/L at the timepoint. The Lower GLOBE PBC score predicts lower risk and better prognosis.

Time frame:
At Week 52
Reported as:
Mean · Scores on a scale
Global PBC Study Group (GLOBE) Score at Week 52
Scores on a scaleElafibranor 80 mgPlacebo
Global PBC Study Group (GLOBE) Score at Week 52-1.03 ± 0.70-0.62 ± 0.83
SecondaryChange From Baseline in Hepatobiliary Injury and Liver Function as Assessed by AST, ALT, Gamma-glutamyl Transferase (GGT), 5 Prime Nucleotidase (5'-NT), and Fractionated ALP (Hepatic) (H1 and H2) at Week 52

Hepatobiliary injury and liver function were assessed as measured by AST, ALT, GGT, 5'-NT, and fractionated ALP (hepatic) (H1 and H2). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · U/L
Change From Baseline in Hepatobiliary Injury and Liver Function as Assessed by AST, ALT, Gamma-glutamyl Transferase (GGT), 5 Prime Nucleotidase (5'-NT), and Fractionated ALP (Hepatic) (H1 and H2) at Week 52
U/LElafibranor 80 mgPlacebo
AST-2.5 ± 17.8-4.3 ± 24.3
ALT-9.7 ± 22.1-6.3 ± 26.3
GGT-44.0 ± 95.6-17.3 ± 112.7
5'-NT-3.63 ± 5.40-2.09 ± 10.52
Hepatic ALP H1-107.68 ± 77.17-32.20 ± 71.42
Hepatic ALP H2-11.76 ± 14.67-5.20 ± 54.83
SecondaryChange From Baseline in Hepatobiliary Injury and Liver Function as Measured by Total and Conjugated Bilirubin at Week 52

Hepatobiliary injury and liver function were assessed as measured by total and conjugated bilirubin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · Micromoles per liter (μmol/L)
Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by Total and Conjugated Bilirubin at Week 52
Micromoles per liter (μmol/L)Elafibranor 80 mgPlacebo
Total Bilirubin-0.67 ± 3.180.87 ± 4.29
Conjugated bilirubin-0.09 ± 1.980.61 ± 2.41
SecondaryChange From Baseline in Hepatobiliary Injury and Liver Function as Measured by Albumin at Week 52

Hepatobiliary injury and liver function were assessed as measured by albumin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by Albumin at Week 52
Grams per liter (g/L)Elafibranor 80 mgPlacebo
Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by Albumin at Week 521.0 ± 2.8-1.2 ± 2.7
SecondaryChange From Baseline in Hepatobiliary Injury and Liver Function as Measured by INR at Week 52

Hepatobiliary injury and liver function were assessed as measured by INR. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · Ratio
Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by INR at Week 52
RatioElafibranor 80 mgPlacebo
Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by INR at Week 520.028 ± 0.1480.035 ± 0.131
SecondaryChange From Baseline in Biomarkers of Inflammation as Measured by High-sensitivity C-reactive Protein (hsCRP) at Week 52

Biomarkers of inflammation were assessed as measured by hsCRP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · mg/L
Change From Baseline in Biomarkers of Inflammation as Measured by High-sensitivity C-reactive Protein (hsCRP) at Week 52
mg/LElafibranor 80 mgPlacebo
Change From Baseline in Biomarkers of Inflammation as Measured by High-sensitivity C-reactive Protein (hsCRP) at Week 52-1.38 ± 6.530.22 ± 2.64
SecondaryChange From Baseline in Biomarkers of Inflammation as Measured by Fibrinogen and Haptoglobin at Week 52

Biomarkers of inflammation were assessed as measured by fibrinogen and haptoglobin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · g/L
Change From Baseline in Biomarkers of Inflammation as Measured by Fibrinogen and Haptoglobin at Week 52
g/LElafibranor 80 mgPlacebo
Fibrinogen-1.002 ± 1.303-0.776 ± 1.265
Haptoglobin-0.185 ± 0.4070.023 ± 0.302
SecondaryChange From Baseline in Biomarkers of Inflammation as Measured by Tumor Necrosis Factor Alpha at Week 52

Biomarkers of inflammation were assessed as measured by TNF-alpha. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · Picograms per milliliter (pg/mL)
Change From Baseline in Biomarkers of Inflammation as Measured by Tumor Necrosis Factor Alpha at Week 52
Picograms per milliliter (pg/mL)Elafibranor 80 mgPlacebo
Change From Baseline in Biomarkers of Inflammation as Measured by Tumor Necrosis Factor Alpha at Week 52-3.346 ± 15.442-0.224 ± 0.921
SecondaryChange From Baseline in Immune Response as Measured by Immunoglobulin (Ig)G and IgM at Week 52

Immune response was assessed as measured by IgG and IgM. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · g/L
Change From Baseline in Immune Response as Measured by Immunoglobulin (Ig)G and IgM at Week 52
g/LElafibranor 80 mgPlacebo
IgG-0.423 ± 1.5910.298 ± 1.159
IgM-0.606 ± 0.9070.017 ± 0.762
SecondaryChange From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Enhanced Liver Fibrosis (ELF) and Plasminogen Activator Inhibitor-1 (PAI-1) at Week 52

Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by ELF: hyaluronic acid \[HA\], type 2 procollagen peptide \[PIINP\], tissue inhibitor of metalloproteinases-1\[TIMP-1\]) and PAI-1. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · Micrograms per liter (mcg/L)
Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Enhanced Liver Fibrosis (ELF) and Plasminogen Activator Inhibitor-1 (PAI-1) at Week 52
Micrograms per liter (mcg/L)Elafibranor 80 mgPlacebo
HA7.93 ± 80.3516.36 ± 48.60
PIINP-2.79 ± 32.55-5.60 ± 20.03
TIMP-1-3.03 ± 51.0623.26 ± 65.03
PAI-10.053 ± 3.0320.785 ± 7.028
SecondaryChange From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Cytokeratin-18 (CK-18) at Week 52

Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by CK-18 (M30 and M65). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · Picomoles per liter (pmol/L)
Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Cytokeratin-18 (CK-18) at Week 52
Picomoles per liter (pmol/L)Elafibranor 80 mgPlacebo
CK-18 M30-70.71 ± 444.31-5.39 ± 334.22
CK-18 M65-50.02 ± 246.28-83.73 ± 481.30
SecondaryChange From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Transforming Growth Factor Beta (TGF-beta) at Week 52

Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by TGF-beta. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · pg/mL
Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Transforming Growth Factor Beta (TGF-beta) at Week 52
pg/mLElafibranor 80 mgPlacebo
Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Transforming Growth Factor Beta (TGF-beta) at Week 52713.074 ± 6553.956-6172.360 ± 3279.127
SecondaryChange From Baseline in Liver Stiffness Measured by Transient Elastography (TE) at Week 52

FibroScan® TE device (Echosens, Paris, France) is a non-invasive technique used to measure liver stiffness, which correlated with fibrosis. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · Kilopascal (kPa)
Change From Baseline in Liver Stiffness Measured by Transient Elastography (TE) at Week 52
Kilopascal (kPa)Elafibranor 80 mgPlacebo
Change From Baseline in Liver Stiffness Measured by Transient Elastography (TE) at Week 52-0.16 ± 3.700.35 ± 6.39
SecondaryChange From Baseline in Lipid Parameters at Week 52

Blood samples were collected at specified timepoints for assessment of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol and triglycerides (TG). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · Millimoles per liter (mmol/L)
Change From Baseline in Lipid Parameters at Week 52
Millimoles per liter (mmol/L)Elafibranor 80 mgPlacebo
Total cholesterol-0.532 ± 0.910-0.318 ± 1.144
LDL cholesterol-0.428 ± 0.730-0.274 ± 1.086
HDL cholesterol0.011 ± 0.364-0.056 ± 0.399
VLDL cholesterol-0.118 ± 0.1590.015 ± 0.156
TG-0.268 ± 0.3700.031 ± 0.343
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 52

Blood samples were collected at specified timepoints for assessment of FPG. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52
mmol/LElafibranor 80 mgPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52-0.267 ± 0.8610.086 ± 0.381
SecondaryChange From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis at Week 52

Blood samples were collected at specified timepoints for assessment bile acids and biomarkers of bile acid synthesis. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · µmol/L
Change From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis at Week 52
µmol/LElafibranor 80 mgPlacebo
Chenodeoxycholic acid0.177 ± 0.8070.100 ± 0.527
Cholic acid0.156 ± 0.6560.027 ± 0.337
Deoxycholic acid-0.027 ± 0.288-0.039 ± 0.360
Glycochenodeoxycholic acid-0.564 ± 3.3100.581 ± 4.408
Glycocholic acid-0.370 ± 2.4222.253 ± 12.291
Glycodeoxycholic acid-0.516 ± 1.247-0.266 ± 2.688
Glycolithocholic acid-0.0234 ± 0.0762-0.0187 ± 0.1768
Lithocholic acid-0.010 ± 0.047-0.003 ± 0.047
Taurochenodeoxycholic acid-0.085 ± 2.4950.857 ± 3.048
Taurocholic acid0.070 ± 2.0591.127 ± 4.380
Taurodeoxycholic acid-0.0828 ± 0.4412-0.0343 ± 0.3683
Taurolithocholic acid-0.0098 ± 0.0424-0.0082 ± 0.0684
SecondaryChange From Baseline at Week 52 in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured by 7 Alpha-hydroxy-4-cholesten-3-one (C4) at Week 52

Blood samples were collected at specified timepoints for assessment of bile acids and biomarkers of bile acid synthesis as measured by C4. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · mcg/L
Change From Baseline at Week 52 in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured by 7 Alpha-hydroxy-4-cholesten-3-one (C4) at Week 52
mcg/LElafibranor 80 mgPlacebo
Change From Baseline at Week 52 in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured by 7 Alpha-hydroxy-4-cholesten-3-one (C4) at Week 52-7.288 ± 16.779-4.044 ± 12.995
SecondaryChange From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured Fibroblast Growth Factor 19 at Week 52

Blood samples were collected at specified timepoints for assessment bile acids and biomarkers of bile acid synthesis as measured by Fibroblast Growth Factor 19. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · pg/mL
Change From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured Fibroblast Growth Factor 19 at Week 52
pg/mLElafibranor 80 mgPlacebo
Change From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured Fibroblast Growth Factor 19 at Week 52-12.89 ± 80.2454.54 ± 343.47
SecondaryPercentage of Participants With Response in PBC Worst Itch NRS Score at Weeks 24 and 52

The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Response to PBC Worst Itch NRS was according to clinically meaningful change at least 30% reduction; one point, two points or three points decrease in score from baseline in participants with a baseline NRS score ≥4. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).

Time frame:
Baseline (up to 14 days pre-dose) and at Week 24 and Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Response in PBC Worst Itch NRS Score at Weeks 24 and 52
Percentage of participantsElafibranor 80 mgPlacebo
Week 24: 30% reduction from baseline43.628.6
Week 52: 30% reduction from baseline55.633.3
Week 24: One-point decrease from baseline53.842.9
Week 52: One-point decrease from baseline61.138.9
Week 24: Two-point decrease from baseline38.528.6
Week 52: Two-point decrease from baseline47.233.3
Week 24: Three-point decrease from baseline28.219.0
Week 52: Three-point decrease from baseline41.733.3
SecondaryPercentage of Participants With no Worsening of Pruritus as Measured by the PBC Worst Itch NRS Score at Weeks 24 and 52

The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake). A worsening of Pruritus was defined by a positive change from baseline in PBC Worst Itch NRS score greater than 2 at week 24 and 52.

Time frame:
Baseline (up to 14 days pre-dose) and at Week 24 and Week 54
Reported as:
Number · Percentage of participants
Percentage of Participants With no Worsening of Pruritus as Measured by the PBC Worst Itch NRS Score at Weeks 24 and 52
Percentage of participantsElafibranor 80 mgPlacebo
Week 2489.286.3
Week 5276.782.6
SecondaryChange From Baseline in 5-D Itch at Week 52

The 5-D Itch scale is a questionnaire that has been validated in several different diseases. It assesses symptoms in terms of 5 domains: duration: score range 1 (less than 6 hours) to 5 (all day); degree: score range 1 (not present) to 5 (unbearable); duration: score range 1 (less than 6 hours) and 5 (all day); direction: score range 1(completely resolved) and 5 (getting worse); disability: score range 1 (never affects or not applicable) and 5 (delays falling asleep and frequently wakes up at night or always affects this activity) and distribution: where the question was to mark where itching is present in body parts over the last two weeks. Participants rated their symptoms over preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. The 5-D Itch total score ranged between 5 (no pruritus) and 25 (most severe pruritus). Higher scores indicated worse outcomes. Baseline= last non-missing value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in 5-D Itch at Week 52
Scores on a scaleElafibranor 80 mgPlacebo
Change From Baseline in 5-D Itch at Week 52-1.9 (-2.6 to -1.3)-0.6 (-1.6 to 0.3)
SecondaryChange From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a at Week 52

The PROMIS Fatigue Short Form 7a consists of seven items that measure both the experience of fatigue and the interference of fatigue on daily activities over the past week. Participants completed the PROMIS Fatigue Short Form 7a and answered following questions on a scale from 1 (never) to 5 (always) : "How often did you feel tired"; "How often did you experience extreme exhaustion"; "How often did you run out of energy"; "How often did your fatigue limit you at work"; "How often were you too tired to think clearly"; "How often were you too tired to take a bath or shower" and 'How often did you have enough energy to exercise strenuously". T-score values include mean of 50 and standard deviation of 10. The PROMIS Fatigue T-score ranged from 29.4 (best) to 83.2 (worst). Higher scores indicated worse outcomes. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Least squares mean · T-score
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a at Week 52
T-scoreElafibranor 80 mgPlacebo
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a at Week 52-2.45 (-3.84 to -1.07)-1.23 (-3.22 to 0.77)
SecondaryChange From Baseline in Epworth Sleepiness Scale (ESS) at Week 52

The ESS is a short, self-administered questionnaire that consists of 8 questions asking to rate how likely it is to fall asleep in everyday situations (each question can be scored from 0 to 3 points; '0' indicates no chance of dozing and '3' indicates high chance of dozing). It provides a total score which has been shown to relate to the participant's level of daytime sleepiness (total score range 0 \[no sleepiness\] to 24 points \[significant sleepiness\]). The total score is the sum of all item scores and ranged from 0 (best) to 24 (worst). Higher scores indicated more chances of sleepiness. Participants were asked to complete the ESS with regard to the level of sleepiness they experienced over approximately the past 7 days. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Epworth Sleepiness Scale (ESS) at Week 52
Scores on a scaleElafibranor 80 mgPlacebo
Change From Baseline in Epworth Sleepiness Scale (ESS) at Week 52-0.3 (-1.1 to 0.5)-0.5 (-1.7 to 0.6)
SecondaryChange From Baseline in PBC-40 at Week 52

PBC-40 assess symptoms across 6 domains:symptoms,itch,fatigue,cognitive,emotional and social. Participants responded on verbal response scale,depending on section options range from 'never'/'not at all'/'strongly disagree' to 'always'/'very much'/'strongly agree'.5 items (3/3 in itch domain and 2/10 in social domain)also included a 'does not apply' option.Domains:Symptoms(7 questions)score range 7-35,Itch(3 questions)score range 3-15,Fatigue(11 questions)score range 11-55,Cognitive(6 questions)score range 6-30,Emotional(3 questions)score range 3-15,Social(10 questions)score range 10-50.Score for each domain was provided(total score was not calculated),with each verbal response scale correlating to score of 1-5 per item(0-5 on items with a 'does not apply' option);5=most affected.Individual item scores are summed to give total domain score.Higher scores=worse outcomes.PBC-40 had 4-week recall period.Baseline=last non-missing value on or before first dose of randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in PBC-40 at Week 52
Scores on a scaleElafibranor 80 mgPlacebo
Symptoms0.2 (-0.5 to 0.8)-0.9 (-1.8 to 0.1)
Itch-1.4 (-1.8 to -0.9)-0.2 (-0.9 to 0.5)
Fatigue-1.5 (-2.7 to -0.2)-1.2 (-3.0 to 0.7)
Cognitive-0.6 (-1.4 to 0.2)-0.7 (-1.8 to 0.4)
Emotional-0.8 (-1.2 to -0.3)-0.6 (-1.2 to 0.1)
Social-1.1 (-2.3 to 0.1)-0.4 (-2.1 to 1.3)
SecondaryChange From Baseline in Health Utility as Measured by the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) at Week 52

The EQ-5D-5L is a 6-item, standardized questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health state. The visual analog scale (VAS) of EQ-5D-5L questionnaire is numbered from 0 (worst) to 100 (best). Higher scores indicated better outcomes. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Health Utility as Measured by the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) at Week 52
Scores on a scaleElafibranor 80 mgPlacebo
Change From Baseline in Health Utility as Measured by the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) at Week 522.5 (0.0 to 4.9)1.6 (-1.9 to 5.0)
SecondaryChange From Baseline in T-Scores for Bone Mineral Density Assessed by Dual-energy X-ray Absorptiometry (DEXA) Scanning at Week 52

DEXA scanning (hip and lumbar) was performed in participants to assess bone mineral density (femoral neck, lumbar and total hip). T-scores were calculated based on actual measured bone density value. The T-score compared a participant's bone density against that of a healthy 30-year-old adult. T-scores were used to determine primary osteoporosis, which exists on its own without any other cause and were divided into 3 categories: low risk, medium risk, and high risk (osteoporosis). T-scores measure the number of minerals in a participant's bone. A participant's level of bone loss was compared to that of a typical, healthy 30-year-old adult. A score ≥-1.0 indicates low risk, medium risk is a score between-2.5 and -1.0, and a high risk/osteoporosis is a score ≤-2.5. A positive change in T-score indicates an improvement in bone mineral density. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · T-score
Change From Baseline in T-Scores for Bone Mineral Density Assessed by Dual-energy X-ray Absorptiometry (DEXA) Scanning at Week 52
T-scoreElafibranor 80 mgPlacebo
Femoral Neck Bone Mineral Density T-score-0.016 ± 0.402-0.111 ± 0.533
Lumbar Bone Mineral Density T-score-0.006 ± 0.487-0.022 ± 0.405
Total Hip Bone Mineral Density T-score0.039 ± 0.529-0.371 ± 0.618
SecondaryChange From Baseline in Serum Markers of Bone Turnover Carboxy Terminal Crosslinked Telopeptides of Type 1 Collagen [CTX] at Week 52

Blood samples were collected at specified timepoints for assessment of serum markers of bone turnover, CTX. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · pg/mL
Change From Baseline in Serum Markers of Bone Turnover Carboxy Terminal Crosslinked Telopeptides of Type 1 Collagen [CTX] at Week 52
pg/mLElafibranor 80 mgPlacebo
Change From Baseline in Serum Markers of Bone Turnover Carboxy Terminal Crosslinked Telopeptides of Type 1 Collagen [CTX] at Week 5236.5 ± 212.644.5 ± 129.7
SecondaryChange From Baseline in Serum Markers of Bone Turnover Type 1 Procollagen Peptide [P1NP]) at Week 52

Blood samples were collected at specified timepoints for assessment of serum markers of bone turnover, P1NP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.

Time frame:
Baseline (Day 1) and at Week 52
Reported as:
Mean · mcg/L
Change From Baseline in Serum Markers of Bone Turnover Type 1 Procollagen Peptide [P1NP]) at Week 52
mcg/LElafibranor 80 mgPlacebo
Change From Baseline in Serum Markers of Bone Turnover Type 1 Procollagen Peptide [P1NP]) at Week 52-2.79 ± 32.55-5.60 ± 20.03
SecondaryPercentage of Participants With Onset of Clinical Outcomes

Onset of clinical outcomes were described as a composite endpoint composed of the following: model for end stage liver disease sodium (MELD-Na) \>14 for participants with baseline MELD-Na \<12; liver transplant; uncontrolled ascites requiring treatment; hospitalization for new onset or recurrence of any including, variceal bleed, hepatic encephalopathy defined as West-Haven score of 2 or more and spontaneous bacterial peritonitis; and death.

Time frame:
From Day 1 up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Onset of Clinical Outcomes
Percentage of participantsElafibranor 80 mgPlacebo
Meld-Na > 14 while baseline Meld-Na < 120.90.0
Liver transplant0.00.0
Uncontrolled ascites requiring treatment0.90.0
Hospitalization for new onset or recurrence of variceal bleed0.00.0
Hospitalization for new onset or recurrence of Hepatic encephalopathy0.00.0
Hospitalization for new onset or recurrence of Spontaneous bacterial peritonitis0.00.0
Death0.90.0
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)

An AE was any untoward medical occurrence in a participant or clinical investigation participant who was administered an investigational product, and which does not necessarily have a causal relationship with treatment. A TEAE was defined as any AE with onset during TEAE assessment period, or any event started prior to first dose of treatment and worsened or became serious during the TEAE assessment period. An SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect. An AESI was an AE that might not be serious but was of special importance to a particular treatment or class.

Time frame:
TEAEs were collected from the start of study treatment administration (Day 1) up to DCO date of 01 June 2023, approximately 980 days.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)
ParticipantsElafibranor 80 mgPlacebo
TEAEs10448
TESAEs117
AESIs3214
SecondaryPlasma Concentrations of Elafibranor and GFT1007

Blood samples were collected at specified timepoints to evaluate plasma concentration of Elafibranor and its metabolite GFT1007.

Time frame:
Week 4: pre-dose, 0.5 hour, 1.5 hours, between 2-3 hours, 4 hours and 6 hours post-dose
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Plasma Concentrations of Elafibranor and GFT1007
Nanograms per milliliter (ng/mL)Elafibranor 80 mg
Elafibranor: Week 4: Pre-dose92.7 ± 52.9
Elafibranor: Week 4: 0.5 hour post-dose408.2 ± 104.1
Elafibranor: Week 4: 1.5 hours post-dose281.7 ± 66.1
Elafibranor: Week 4: between 2-3 hours post-dose182.0 ± 67.8
Elafibranor: Week 4: 4 hours post-dose127.7 ± 52.7
Elafibranor: Week 4: 6 hours post-dose117.1 ± 53.5
GFT1007: Week 4: Pre-dose77.3 ± 85.6
GFT1007: Week 4: 0.5 hour post-dose894.6 ± 150.0
GFT1007: Week 4: 1.5 hours post-dose1707.2 ± 52.1
GFT1007: Week 4: between 2-3 hours post-dose1160.8 ± 53.9
GFT1007: Week 4: 4 hours post-dose655.8 ± 54.7
GFT1007: Week 4: 6 hours post-dose375.7 ± 65.9

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were reported from the start of study treatment administration (Day 1) up to DCO date of 01 June 2023, approximately 980 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elafibranor 80 mg2/108 (1.9%)11/108 (10.2%)103/108 (95.4%)
Placebo0/53 (0%)7/53 (13.2%)47/53 (88.7%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventElafibranor 80 mgPlacebo
Acute kidney injuryRenal and urinary disorders3/1081/53
COVID-19Infections and infestations0/1081/53
Urinary tract infectionInfections and infestations0/1081/53
Procedural painInjury, poisoning and procedural complications0/1081/53
SyncopeNervous system disorders0/1081/53
PainGeneral disorders0/1081/53
CataractEye disorders0/1081/53
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1081/53
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1081/53
AnxietyPsychiatric disorders0/1081/53
Most frequent other events
Showing 10 of 20
Most frequent other events
EventElafibranor 80 mgPlacebo
COVID-19Infections and infestations31/10819/53
PruritusSkin and subcutaneous tissue disorders22/10814/53
Abnormal weight gainMetabolism and nutrition disorders21/10810/53
Urinary tract infectionInfections and infestations12/1089/53
FatigueGeneral disorders10/1087/53
Back painMusculoskeletal and connective tissue disorders4/1086/53
HeadacheNervous system disorders9/1086/53
DiarrhoeaGastrointestinal disorders12/1085/53
NauseaGastrointestinal disorders12/1083/53
VomitingGastrointestinal disorders12/1081/53

Baseline characteristics

The Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(Years)Elafibranor 80 mgPlaceboTotal
Mean57.5 ± 8.456.4 ± 9.357.1 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Elafibranor 80 mgPlaceboTotal
Female10252154
Male617
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Elafibranor 80 mgPlaceboTotal
White10146147
Black or African American202
Asian134
American Indian or Alaska Native011
Other325
Not Reported112
08

Study locations

115 sites

Showing the first 100 of 115 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kowdley KV, Bowlus CL, Levy C, Akarca U, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Elbeshbeshy H, Francque S, Heneghan MA, Invernizzi P, Jacobson IM, Jones D, Kremer AE, Kruger FC, Kugelmas M, Lawitz E, Mayo MJ, Shiffman ML, Sonderup M, Swain MG, Valera JM, Vierling JM, Villagrasa A, Villamil A, Antunes N, Raskino C, Sleiman M, Cranham V, Miller B, Schattenberg JM. Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE(R) phase III trial. J Hepatol. 2026 Aug 27:S0168-8278(26)02859-X. doi: 10.1016/j.jhep.2026.08.016. Online ahead of print. PubMed 42660235 ↗
  • Levy C, Bowlus CL, Lawitz E, Antunes N, Miller B, Shu J, Zein CO, Kowdley KV. Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE. Liver Int. 2026 May;46(5):e70630. doi: 10.1111/liv.70630. PubMed 41937506 ↗
  • Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Tadde B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators' Group; ELATIVE Study Investigators' Group. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. PubMed 37962077 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jun 2023, 32 months.

Results were first posted in Sep 2024, 1 year 3 months after primary completion. A results delay was requested in May 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2020
First posted
Aug 26, 2020
StartActual
Sep 24, 2020
Primary completionActual
Jun 1, 2023
CompletionEst.
Dec 1, 2028
Results delay requested
May 9, 2024
Results first posted
Sep 5, 2024
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 21, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04526665
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Aug 26, 2020
Start date
Sep 24, 2020
Primary completion
Jun 1, 2023
Completion
Dec 1, 2028 (estimated)
Results posted
Sep 5, 2024
Last update
Nov 5, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion